Table 1.
Baseline Clinical Characteristics of Patients
Characteristics | Value |
---|---|
Gender, n (%) | |
Male | 8(80.0) |
Mean±SD | 58.7±7.85 |
Female | 2(20.0) |
Age (years) | |
Median | 56 |
Range | 46–71 |
Weight | |
≥60kg | 5(50.0) |
<60kg | 5(50.0) |
Etiology, n (%) | |
HBV | 3(30.0) |
Unknow | 7(70.0) |
ECOG, n (%) | |
1 | 7(70.0) |
2 | 3(30.0) |
Child–Pugh class, n (%) | |
A | 7(70.0) |
B | 3(30.0) |
Serum CA19-9, n (%) | |
≥27U/mL | 6(60.0) |
<27U/mL | 4(40.0) |
Tumor size(cm), n (%) | |
Mean±SD | 6.84±4.41 |
≥5cm | 7(70.0) |
<5cm | 3(30.0) |
Number of tumors, n (%) | |
1–3 | 4(40.0) |
>3 | 6(60.0) |
Macroscopic vascular invasion, n (%) | |
Yes | 3(30.0) |
No | 7(70.0) |
Metastatic sites, n (%) | |
Regional lymph nodes | 10(100.0) |
Distant lymph nodes | 3(30.0) |
Lung | 6(60.0) |
Bone | 4(40.0) |
Biliary drainage | |
Yes | 2(20.0) |
No | 8(80.0) |
Previous therapy, n (%) | |
No | 5(50.0) |
Chemotherapy | 1(10.0) |
Radiotherapy | 1(10.0) |
Resection and chemoradiotherapy | 2(20.0) |
TACE | 1(10.0) |
Disease stage, n (%) | |
IIIB | 3(30.0) |
IV | 7(70.0) |
Abbreviations: HBV, hepatitis B virus; ECOG, Eastern Cooperative Oncology Group; CA19-9, carbohydrate antigen 19–9; TACE, transarterial chemoembolization.